Roch Doliveux, the chief executive of UCB SA, has been appointed to a second term as chair of the Innovative Medicines Initiative (IMI), a public-private research partnership. The IMI is supported jointly by the European Commission and the European industry federation Efpia.
Dr Doliveux joined the IMI Governing Board in May 2010, and was chairman from 2012 to 2013. The IMI currently supports 46 projects with a combined budget of around €1.6 billion.
Copyright 2014 Evernow Publishing Ltd